Insider · CIK 0002047493
James P. Quinlan
Files at MDCX (Medicus Pharma Ltd.). First filing -, latest -.
In brief
James P. Quinlan files SEC Form 4 as CFO at MDCX (Medicus Pharma Ltd.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; James P. Quinlan has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 13, 2025 | MDCX Medicus Pharma Ltd. | MOption exercise Common Shares, no par value ("Common Shares") | +125,000 | $0.81 | $101k | 254,147 | Aug 14, 2025 |
| Aug 13, 2025 | MDCX Medicus Pharma Ltd. | MOption exercise Common Shares | +20,000 | $2.75 | $55k | 274,147 | Aug 14, 2025 |
| Aug 13, 2025 | MDCX Medicus Pharma Ltd. | MOption exercise Stock Option (right to buy)derivative | -125,000 | $0.00 | $0 | 0 | Aug 14, 2025 |
| Aug 13, 2025 | MDCX Medicus Pharma Ltd. | MOption exercise Stock Option (right to buy)derivative | -20,000 | $0.00 | $0 | 0 | Aug 14, 2025 |
| Jul 22, 2025 | MDCX Medicus Pharma Ltd. | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jul 24, 2025 |
Questions about James P. Quinlan
Answered from the filings on this page, as of the latest one.
Is James P. Quinlan buying or selling?
James P. Quinlan has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did James P. Quinlan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James P. Quinlan has 0.
Where does James P. Quinlan file Form 4?
James P. Quinlan has filed Form 4 at MDCX (Medicus Pharma Ltd.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.